Home/Filings/4/0000899243-17-022303
4//SEC Filing

Tanaka Masaharu 4

Accession 0000899243-17-022303

CIK 0001631574other

Filed

Sep 18, 8:00 PM ET

Accepted

Sep 19, 9:09 PM ET

Size

10.7 KB

Accession

0000899243-17-022303

Insider Transaction Report

Form 4
Period: 2017-09-15
Tanaka Masaharu
Director10% Owner
Transactions
  • Sale

    Ordinary Shares

    2017-09-18$24.19/sh6,362$153,8972,774,118 total(indirect: See Footnote)
  • Sale

    Ordinary Shares

    2017-09-15$24.22/sh14,385$348,4052,780,480 total(indirect: See Footnote)
Transactions
  • Sale

    Ordinary Shares

    2017-09-15$24.22/sh14,385$348,4052,780,480 total(indirect: See Footnote)
  • Sale

    Ordinary Shares

    2017-09-18$24.19/sh6,362$153,8972,774,118 total(indirect: See Footnote)
Footnotes (4)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.60 to $24.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka previously was a director of the Issuer and the representative director of Kagoshima Development Co., Ltd., the general partner of KSS. Mr. Tanaka resigned as a director of the Issuer and resigned as an employee of Kagoshima Development Co., Ltd. and, as a result of the resignations, may no longer be deemed to beneficially own the securities previously reported in prior Form 3 and Form 4 filings filed jointly with KSS. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.
  • [F3](Continued from footnote 2) As a result of Mr. Tanaka's resignation as director and the reduction in the number of Ordinary Shares beneficially owned upon the sale of Ordinary Shares reported in Table I, Mr. Tanaka and KSS are no longer subject to Section 16 of the Securities Exchange Act of 1934, as amended.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

Wave Life Sciences Ltd.

CIK 0001631574

Entity typeother

Related Parties

1
  • filerCIK 0001657771

Filing Metadata

Form type
4
Filed
Sep 18, 8:00 PM ET
Accepted
Sep 19, 9:09 PM ET
Size
10.7 KB